Summary & Overview
Chemotherapy without Acute Leukemia as Secondary Diagnosis without CC/MCC: Inpatient Reimbursement Overview
DRG 848 encompasses inpatient admissions for chemotherapy when acute leukemia is not present as a secondary diagnosis and there are no Complication or Comorbidity or Major Complication or Comorbidity present. This classification defines the expected resource use and sets the standardized Medicare payment rate for such uncomplicated chemotherapy hospital stays.
DRG 848 Overview
DRG 848 covers inpatient hospital stays where chemotherapy is the primary reason for admission and acute leukemia is not listed as a secondary diagnosis, without any Complication or Comorbidity or Major Complication or Comorbidity. This Diagnosis-Related Group groups patients with relatively straightforward chemotherapy needs and lower resource use compared with cases that have major complications. It matters for Medicare payment because it establishes the prospective payment rate for these admissions under the inpatient prospective payment system. Accurate assignment affects hospital reimbursement and billing categorization.
Clinical Trials
- Trials evaluating outpatient versus inpatient chemotherapy administration protocols for non-acute leukemia malignancies: These studies compare safety, toxicity monitoring schedules, and resource utilization when systemic chemotherapy is delivered in outpatient infusion centers versus short-stay inpatient admissions for patients without acute leukemia but requiring complex regimens. The patient population includes adults receiving cytotoxic or targeted therapies who have comorbidities or social circumstances that historically prompted inpatient delivery; results inform hospital admission criteria, early-discharge pathways, and payer policy on site-of-care reimbursement.
- Comparative effectiveness studies of supportive care bundles to reduce admission-related complications: Research in this area tests standardized supportive care interventions (antiemetic and hydration protocols, febrile neutropenia prophylaxis algorithms, and symptom monitoring) among patients hospitalized for chemotherapy without acute leukemia to determine which bundles reduce length of stay, readmissions, and treatment interruptions. The trials typically enroll patients receiving moderately to highly myelosuppressive regimens for solid tumors or hematologic conditions other than acute leukemia; findings are directly relevant to clinicians and payers by identifying protocols that improve safety while lowering hospitalization costs.
- Post-discharge outcomes and coordination-of-care studies focusing on transitional care and utilization: These observational and interventional studies assess the impact of structured discharge planning, home health nursing, telemonitoring, and early outpatient follow-up on 30-day readmissions, emergency visits, and adherence to subsequent treatment cycles for patients discharged after chemotherapy-only admissions. The population includes patients who required inpatient stays due to treatment administration logistics, toxicity observation, or social determinants; evidence from these studies guides investment in post-acute services and helps payers evaluate value-based reimbursement strategies to reduce avoidable utilization.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.